Andrew Wilson, MD
Pulmonary Disease · Boston, MANPI 1114000866
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,056 of the $1,297 with a category attached, or 81.4%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 81.4% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $1,056, more than ten times the $32 reported in 2019.
Across 5 payments — averaging $259.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Medtronic$142
- Pfizer$100
Across 4 payments — averaging $50,504 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Shared Services North America, Inc.$202K
What the payments were for
- Consulting fees$1,05681%
- Food & beverage$24119%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,056 |
| Medtronic(2 entities) | 3 | $142 |
| Pfizer | 1 | $100 |
How this compares
$1,297 in reported general payments places this provider in the 65th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 48 | $348,980 |
| GlassiaAlpha-1-Proteinase Inhibitor | 11 | $178,544 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 12 | $132,967 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $130,044 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $1,056 | $178,54411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.